Functional Dissection of Latency-Associated Nuclear Antigen 1 of Kaposi's Sarcoma-Associated Herpesvirus Involved in Latent DNA Replication and Transcription of Terminal Repeats of the Viral Genome

ABSTRACT Latency-associated nuclear antigen 1 (LANA1) of Kaposi's sarcoma-associated herpesvirus (KSHV) is implicated in the maintenance of the viral genome during latent infection. LANA1 colocalizes with KSHV episomes on the host chromosome and mediates their maintenance by attaching these viral structures to host chromosomes. Data from long-term selection of drug resistance in cells conferred by plasmids containing the terminal repeat (TR) sequence of KSHV revealed that KSHV TRs and LANA1 act as cis and trans elements of viral latent replication, respectively. In this study, we further characterized the cis- and trans-acting elements of KSHV latent replication by using a transient replication assay with a methylation-sensitive restriction enzyme, DpnI. Transient reporter and replication assays disclosed that the orientation and basal transcriptional activity of TR constructs did not significantly affect the efficiency of replication. However, at least two TR units were necessary for efficient replication. The N-terminal 90 amino acids comprising the chromosome-binding domain of LANA1 were required for the mediation of LANA1 C-terminal DNA-binding and dimerization domains to support the transient replication of KSHV TRs. LANA1 interacted with components of the origin recognition complexes (ORCs), similar to Epstein-Barr virus nuclear antigen 1. Our data suggest that LANA1 recruits ORCs to KSHV TRs for latent replication of the viral genome.

[1]  Jianhong Hu,et al.  Latency-associated Nuclear Antigen (LANA) Cooperatively Binds to Two Sites within the Terminal Repeat, and Both Sites Contribute to the Ability of LANA to Suppress Transcription and to Facilitate DNA Replication* , 2002, The Journal of Biological Chemistry.

[2]  G. Brent,et al.  The Kaposi sarcoma-associated herpesvirus (KSHV) induces cellular interleukin 6 expression: role of the KSHV latency-associated nuclear antigen and the AP1 response element. , 2002, Blood.

[3]  E. Robertson,et al.  The Latency-Associated Nuclear Antigen Encoded by Kaposi's Sarcoma-Associated Herpesvirus Activates Two Major Essential Epstein-Barr Virus Latent Promoters , 2001, Journal of Virology.

[4]  E. Robertson,et al.  Latency-Associated Nuclear Antigen Encoded by Kaposi's Sarcoma-Associated Herpesvirus Interacts with Tat and Activates the Long Terminal Repeat of Human Immunodeficiency Virus Type 1 in Human Cells , 2001, Journal of Virology.

[5]  Jianhong Hu,et al.  DNA Binding and Modulation of Gene Expression by the Latency-Associated Nuclear Antigen of Kaposi's Sarcoma-Associated Herpesvirus , 2001, Journal of Virology.

[6]  H. Xu,et al.  Human DNA replication initiation factors, ORC and MCM, associate with oriP of Epstein–Barr virus , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[7]  C. Lim,et al.  The Transcriptional Activity of cAMP Response Element-binding Protein-binding Protein Is Modulated by the Latency Associated Nuclear Antigen of Kaposi's Sarcoma-associated Herpesvirus* , 2001, The Journal of Biological Chemistry.

[8]  E. Kremmer,et al.  Human origin recognition complex binds to the region of the latent origin of DNA replication of Epstein–Barr virus , 2001, The EMBO journal.

[9]  Anindya Dutta,et al.  Replication from oriP of Epstein-Barr Virus Requires Human ORC and Is Inhibited by Geminin , 2001, Cell.

[10]  E. Robertson,et al.  The Latency-associated Nuclear Antigen of Kaposi's Sarcoma-associated Herpesvirus Transactivates the Telomerase Reverse Transcriptase Promoter* , 2001, The Journal of Biological Chemistry.

[11]  T. Piolot,et al.  Close but Distinct Regions of Human Herpesvirus 8 Latency-Associated Nuclear Antigen 1 Are Responsible for Nuclear Targeting and Binding to Human Mitotic Chromosomes , 2001, Journal of Virology.

[12]  M. Ballestas,et al.  Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen 1 Mediates Episome Persistence through cis-Acting Terminal Repeat (TR) Sequence and Specifically Binds TR DNA , 2001, Journal of Virology.

[13]  E. Kieff,et al.  Maintenance of Epstein-Barr virus (EBV) oriP-based episomes requires EBV-encoded nuclear antigen-1 chromosome-binding domains, which can be replaced by high-mobility group-I or histone H1. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[14]  P. Brown,et al.  Modulation of Cellular and Viral Gene Expression by the Latency-Associated Nuclear Antigen of Kaposi's Sarcoma-Associated Herpesvirus , 2001, Journal of Virology.

[15]  C. Lim,et al.  Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) binds ATF4/CREB2 and inhibits its transcriptional activation activity. , 2000, The Journal of general virology.

[16]  A. Krithivas,et al.  Human Herpesvirus 8 LANA Interacts with Proteins of the mSin3 Corepressor Complex and Negatively Regulates Epstein-Barr Virus Gene Expression in Dually Infected PEL Cells , 2000, Journal of Virology.

[17]  C. Boshoff,et al.  The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma–E2F pathway and with the oncogene Hras transforms primary rat cells , 2000, Nature Medicine.

[18]  S. Mahajan,et al.  Carboxy Terminus of Human Herpesvirus 8 Latency-Associated Nuclear Antigen Mediates Dimerization, Transcriptional Repression, and Targeting to Nuclear Bodies , 2000, Journal of Virology.

[19]  G. Nabel,et al.  p53 inhibition by the LANA protein of KSHV protects against cell death , 1999, Nature.

[20]  E. Robertson,et al.  The latency-associated nuclear antigen tethers the Kaposi's sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells. , 1999, Virology.

[21]  D. Ganem,et al.  Transcriptional Activation by the Product of Open Reading Frame 50 of Kaposi’s Sarcoma-Associated Herpesvirus Is Required for Lytic Viral Reactivation in B Cells , 1999, Journal of Virology.

[22]  B. Sugden,et al.  The Linking Regions of EBNA1 Are Essential for Its Support of Replication and Transcription , 1999, Molecular and Cellular Biology.

[23]  M. Ballestas,et al.  Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. , 1999, Science.

[24]  D. Ganem,et al.  Reactivation of Kaposi's sarcoma-associated herpesvirus infection from latency by expression of the ORF 50 transactivator, a homolog of the EBV R protein. , 1998, Virology.

[25]  A. Aiyar,et al.  The plasmid replicon of EBV consists of multiple cis‐acting elements that facilitate DNA synthesis by the cell and a viral maintenance element , 1998, The EMBO journal.

[26]  R. Sun,et al.  A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[27]  P. Moore,et al.  Transcription Mapping of the Kaposi’s Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Genome in a Body Cavity-Based Lymphoma Cell Line (BC-1) , 1998, Journal of Virology.

[28]  L. Rainbow,et al.  The 222- to 234-kilodalton latent nuclear protein (LNA) of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of the latency-associated nuclear antigen , 1997, Journal of virology.

[29]  A. Kirchmaier,et al.  Dominant-negative inhibitors of EBNA-1 of Epstein-Barr virus , 1997, Journal of virology.

[30]  J. Russo,et al.  Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[31]  E. Operskalski,et al.  The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma–associated herpesvirus): Distribution of infection in KS risk groups and evidence for sexual transmission , 1996, Nature Medicine.

[32]  J. Phair,et al.  KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma , 1996, Nature Medicine.

[33]  J. Lieberman,et al.  The Kaposi sarcoma-associated herpesvirus (KSHV) is present as an intact latent genome in KS tissue but replicates in the peripheral blood mononuclear cells of KS patients , 1996, The Journal of experimental medicine.

[34]  R. Sun,et al.  Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection. , 1996, The New England journal of medicine.

[35]  M. McGrath,et al.  Lytic growth of Kaposi's sarcoma–associated herpesvirus (human herpesvirus 8) in culture , 1996, Nature Medicine.

[36]  E. Cesarman,et al.  Primary characterization of a herpesvirus agent associated with Kaposi's sarcomae , 1996, Journal of virology.

[37]  B. Stillman,et al.  Conserved Initiator Proteins in Eukaryotes , 1995, Science.

[38]  E. Cesarman,et al.  In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences. , 1995, Blood.

[39]  E. Cesarman,et al.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. , 1995, The New England journal of medicine.

[40]  P. Moore,et al.  Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and those without HIV infection. , 1995, The New England journal of medicine.

[41]  E. Cesarman,et al.  Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. , 1994, Science.

[42]  B. Sugden,et al.  Retention of plasmid DNA in mammalian cells is enhanced by binding of the Epstein-Barr virus replication protein EBNA1 , 1994, Journal of virology.

[43]  M. Botchan,et al.  The E1 protein of bovine papilloma virus 1 is an ATP-dependent DNA helicase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[44]  I. Lehman,et al.  The herpes simplex virus 1 origin binding protein: a DNA helicase. , 1991, The Journal of biological chemistry.

[45]  J. Yates,et al.  Epstein-Barr virus-derived plasmids replicate only once per cell cycle and are not amplified after entry into cells , 1991, Journal of virology.

[46]  G. Hayward,et al.  Definition of the sequence requirements for binding of the EBNA-1 protein to its palindromic target sites in Epstein-Barr virus DNA , 1990, Journal of virology.

[47]  A. Adams.  Replication of latent Epstein-Barr virus genomes in Raji cells , 1987, Journal of virology.

[48]  D. Reisman,et al.  trans activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1 , 1986, Molecular and cellular biology.

[49]  R. Knippers,et al.  DNA helicase activity of SV40 large tumor antigen. , 1986, The EMBO journal.

[50]  A. Levine,et al.  Mapping genetic elements of Epstein-Barr virus that facilitate extrachromosomal persistence of Epstein-Barr virus-derived plasmids in human cells , 1985, Molecular and cellular biology.

[51]  G. Hayward,et al.  Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region , 1985, Cell.

[52]  D. Reisman,et al.  A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cis-acting components , 1985, Molecular and cellular biology.

[53]  B. Hirt.  Selective extraction of polyoma DNA from infected mouse cell cultures. , 1967, Journal of molecular biology.